Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Idera Pharmaceuticals has reported favorable safety and efficacy results from a Phase 1b study of IMO-2055, a TLR9 agonist, in combination with Tarceva and Avastin in patients with advanced non-small cell lung cancer (NSCLC).
Subscribe to our email newsletter
The NSCLC trial evaluated four dose levels of IMO-2055 in combination with standard doses of Tarceva and Avastin in thirty-three patients.
In the trial the patients were evaluable for efficacy, and showed a disease control rate of 79%, a median progression-free survival of 5.6 months and a median overall survival of 16 months.
Patients received oral Tarceva at 150mg once per day and Avastin at 15mg/kg once every three weeks and subcutaneous doses of IMO-2055 once per week.
The doses were given until disease progression or other discontinuation criteria were met.
No new or unexpected toxicities were observed and rates of well-known side effects of the three agents were consistent with results from previously presented clinical trials of IMO-2055.
Idera CEO and chairman Sudhir Agrawal said they are encouraged with the results of this trial in heavily pre-treated patients with NSCLC, which is a difficult-to-treat disease with poor prognosis.
"These data support the development of IMO-2055 as an immune modifier to potentiate the anticancer activity of biologically targeted agents," Agrawal added.